CLNP023G12301 / APRICOT
The study is an open-label, single arm, multicenter, Phase III study to determine proteinuria reduction, pharmacokinetics (PK), safety and tolerability (including CV surveillance) of iptacopan in primary immunoglobulin A nephropathy (IgAN) pediatric…
- Investigator
- Lawrence R Shoemaker
- Status
- Accepting Candidates
- Ages
- 2 Years - 18 Years
- Sexes
- All
APL2-C3G-314
This study is designed as a long-term extension to Study APL2-C3G-310, and is being conducted to establish the long-term safety and efficacy of pegcetacoplan in patients with C3 glomerulopathy (C3G) or immune-complex membranoproliferative…
- Investigator
- Lawrence R Shoemaker
- Status
- Accepting Candidates
- Ages
- 12 Years - N/A
- Sexes
- All